Home > Posts > Dr. Steven Kaplan

Dr. Steven Kaplan

Dr. Steven Kaplan
Dr. Steven Kaplan graduated from Mount Sinai School of Medicine in 1982 and was elected to the AOA Honor Society. Dr. Kaplan’s postgraduate training included an internship and residency in the Department of Surgery at Mount Sinai Hospital as well as a residency in Urology at the Squier Urologic Clinic, Columbia University. He was an American Urologic Association Scholar between 1988 – 1990 that focused on identifying molecular markers and urodynamic parameters that herald bladder and prostate dysfunction. Dr. Kaplan was the Given Foundation Professor of Urology and Administrator, as well as Vice Chairman of the Department of Urology at Columbia University from 1998 – 2005. And then, the E Darracott Vaughan Jr. Professor of Urology and Chief, Institute for Bladder and Prostate Health at Weill Cornell Medical College and Director, Iris Cantor Men’s Health Center at New York Presbyterian Hospital. Currently, he is Professor of Urology at the Icahn School of Medicine at Mount Sinai and Director of The Men’s Health Program of the Mount Sinai Health System. He is a serial entrepreneur and a founder of Medidata Solutions Inc., a publicly held corporation and one of the premier electronic data capture companies in the world; Medivizor, Inc., a medical informatics enterprise; Eco – Fusion, a novel health care interface platform and InspiReN, a digital interface analyzing and enhancing the patient experience with health care professionals. Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. He is a recognized authority on the study of benign diseases of the prostate, the association of metabolic factors and voiding dysfunction and a thought leader on digital Men’s Health. He has published more than 1200 articles, 170 abstracts, and has made over 340 presentations in more than 35 countries. He is the co - author of five books and is on the Editorial Board of Urology, Journal of Urology, and Urology Times. Dr. Kaplan has been a member of more than 30 professional organizations, been awarded 5 NIH grants and has received over 13 million dollars in research funding. He was awarded the John K. Lattimer Award for Lifetime Achievement in Urology by the National Kidney Foundation. Currently, he is the Chair of Research of the of American Urologic Association and is on the AUA BPH Guidelines Committee.

Locations

Mount Sinai Urology New York, NY

625 Madison Avenue, 2nd FloorNew York, New York, 10022United States
212-241-1232 | Visit Website

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only